Risk factor
Poor trading liquidity
Profitability factor
Strong margins and returns
About
FDC Limited operates as a global pharmaceutical enterprise, engaged in the production and distribution of a diverse range of medicinal products within India and across international markets. Its extensive product line primarily encompasses specialized formulations designed to address numerous therapeutic areas, including anti-infectives, gastrointestinal conditions, ophthalmological disorders, cardiovascular health, diabetes management, respiratory ailments, gynecology, dermatology, and pain relief, alongside various vitamins, minerals, and dietary supplements. A significant offering also includes oral rehydration salts. These specialized formulations are marketed under prominent brands such as Zifi, Electral (a leading oral rehydration solution), Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. Beyond these, the company also provides antioxidants, balanced energy beverages, and a variety of vitamins and nutraceuticals, offered through brands like Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich. Furthermore, FDC supplies various active pharmaceutical ingredients (APIs). Founded in 1936, FDC Limited maintains its corporate headquarters in Mumbai, India.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E